<bill session="114" type="h" number="1455" updated="2018-11-21T21:22:56Z">
  <state datetime="2015-03-18">REFERRED</state>
  <status>
    <introduced datetime="2015-03-18"/>
  </status>
  <introduced datetime="2015-03-18"/>
  <titles>
    <title type="short" as="introduced">Speeding Access to Already Approved Pharmaceuticals Act of 2015</title>
    <title type="official" as="introduced">To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.</title>
    <title type="display">Speeding Access to Already Approved Pharmaceuticals Act of 2015</title>
  </titles>
  <sponsor bioguide_id="S001187"/>
  <cosponsors>
    <cosponsor bioguide_id="R000577" joined="2015-03-18"/>
  </cosponsors>
  <actions>
    <action datetime="2015-03-18">
      <text>Introduced in House</text>
    </action>
    <action datetime="2015-03-18" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2015-03-20">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Europe"/>
    <term name="European Union"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2015-03-18T04:00:00Z" status="Introduced in House">Speeding Access to Already Approved Pharmaceuticals Act of 2015

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to facilitate the development and expedite the review of a new drug, biological product, or device that has been approved in the European Union.</summary>
  <committee-reports/>
</bill>
